NewAmsterdam Pharma Co N.V.(NAMS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

NewAmsterdam Pharma Co N.V. (NAMS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NAMS at 8.2/100 on a 32-signal composite quality model, placing it at rank #2,931 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), NewAmsterdam Pharma Co N.V. reports quarterly revenue of $3.7M, net income of $-64.1M, free cash flow of $-39.3M. Top institutional holders of NAMS by reported 13-F value include Frazier Life Sciences Management, L.P., Capital World Investors, FMR, based on the most recent SEC filings. NAMS trades on the Nasdaq exchange and files with the SEC under CIK 1936258. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NAMS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NewAmsterdam Pharma Co N.V. directly from SEC EDGAR.